To analyze the genomic differences between multiple myeloma (MM) and plasma cell leukemia (PCL), a total of 30 cases were studied by comparative genomic hybridization (CGH). In five cases with a low proportion of plasma cells (PC) in bone marrow, an enrichment of PC was performed by using...
The current definition of plasma cell leukemia (PCL)— ≥ 20% circulating plasma cells (CPCs) on peripheral smear and plasma cell count ≥ 2 × 109/L—may be too stringent. We reviewed outcomes of 176 multiple myeloma (MM) patients diagnosed between 1971 and 2016, and who ha...
Multiple myeloma (MM) is a neoplastic lymphoproliferative disorder characterized by uncontrolled monoclonal plasma cell proliferation. Among different isotypes of MM, immunoglobulin D (IgD) MM is very rare, representing only 1 to 2% of all isotypes. Chronic myelogenous leukemia (CML) is a neoplastic...
Multiple myeloma (MM) is a tumor of terminally differentiated PCs that home to and expand in the bone marrow.29 Although MM appears to originate in a postgerminal center cell, as suggested by the presence of somatic hypermutation,30,31 much speculation exists concerning the exact cell in which...
Significance of Circulating Plasma Cells in Multiple Myeloma The number of circulating plasma cells (CPC) was determined on mononuclear cell preparations after Giemsa (morphology) and light chain staining (immunocyto... M Zandecki,T Facon,C Preudhomme,... - 《Leukemia & Lymphoma》 被引量: 20...
Using anti-CD38 immunotherapy to enhance anti-tumor T-cell immunity in chronic lymphocytic leukemia (CLL). J. Immunol. 200, 58.17 (2018). Google Scholar Pinto, D. et al. A functional BCR in human IgA and IgM plasma cells. Blood 121, 4110–4114 (2013). Article CAS PubMed Google ...
5b-f). The case was diagnosed as a post-transplant lymphoproliferative disorder with plasmacytic differentiation, compatible with plasma cell myeloma/plasma cell leukemia. Fig. 5 Bone marrow biopsy. (a) H&E, 4×, revealing two areas marked as 1 and 2 (b) H&E 20× from 1(c) H&E ...
Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma 2019, Clinical Lymphoma, Myeloma and Leukemia Citation Excerpt : The lower percentage of CIS in their cohort might have resulted from the lower usage of novel agents in 2000 to 2009...
The necessity for bone marrow aspiration and the lack of highly sensitive assays to detect residual disease present challenges for effective management of multiple myeloma (MM), a plasma cell cancer. We show that a microfluidic cell capture based on CD13
Indolent mantle cell leukemia: a clinicopathological variant characterized by isolated lymphocytosis, interstitial bone marrow involvement, kappa light chain restriction, and good prognosis. Haematologica 2011;96:1121–1127. Article Google Scholar Espinet B, Ferrer A, Bellosillo B et al. Distinction ...